Daptomycin versus teicoplanin in the treatment of osteomyelitis: Results of the Göztepe retrospective cohort study - 08/05/21
, H.A. Erdem a, H. Kahraman a, E. Kurşun b, f, B.M. Suntur c, T. Demirdal d, S.A. Nemli d, M. Dizbay e, M. Ulug f, N. Öztoprak-Cuvalci g, B. Arda a, G. Quliyeva a, M. Tasbakan a, S. Uysal a, H. Sipahi h, S. Aydemir i, S. Ulusoy aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Experience regarding daptomycin for the treatment of osteomyelitis is limited. |
• | In this multicenter retrospective cohort study, the aim was to evaluate the outcomes of osteomyelitis cases having received daptomycin or teicoplanin. |
• | Clinical success at the end of induction therapy was achieved in 32/38 cases in daptomycin cohort vs. 30/34 cases in teicoplanin cohort (p: 0.73). |
• | Although this is a limited experience in a small but well-defined cohort, our data suggest that daptomycin may be a safe alternative to glycopeptides in osteomyelitis treatment. |
Abstract |
Objectives |
Daptomycin is highly effective against Gram-positive multidrug-resistant bacteria. Publications on daptomycin in osteomyelitis treatment are limited.
Patients and methods |
In this multicenter retrospective cohort study, the aim was to evaluate the outcomes of osteomyelitis cases having received daptomycin or teicoplanin. This multicenter retrospective cohort study gathered data from seven centers located in five cities of Turkey. Study inclusion criteria were as follows: (a) magnetic resonance imaging and/or direct X-ray revealed osteomyelitis or biopsy pathologic examination results concomitant with osteomyelitis. Chi-squareand Student t-tests were used for statistical comparison.
Results |
A total of 72 patients, 38 cases in the daptomycin group and 34 cases in the teicoplanin group diagnosed with osteomyelitis fulfilling the study inclusion criteria, were included in the study. Clinical success at the end of induction therapy was achieved in 32/38 cases in the daptomycin cohort vs. 30/34 cases in the teicoplanin cohort (p: 0.73).
Conclusion |
Although this is a limited experience in a small but well-defined cohort, our data suggest that daptomycin may be a safe alternative to glycopeptides in osteomyelitis treatment. A randomized controlled clinical study involving larger cohorts may increase the available evidence.
Le texte complet de cet article est disponible en PDF.Keywords : Bone & joint infections, Lipopeptides, Glycopeptides, Debridement, Vancomycin
Plan
Vol 51 - N° 4
P. 362-367 - juin 2021 Retour au numéro
Article précédent
- Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital
- M. Morgat, K. Bouiller, J.B. Vuillemenot, L. Puget, S. Marty-Quinternet, T. Leblanc, K. Jeannot, C. Chirouze, L. Hustache-Mathieu, Q. Lepiller
- Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients
- R. Palich, Y. Wakim, O. Itani, O. Paccoud, S. Boussouar, M. Lévy-Soussan, C. Soulie, N. Godefroy, A. Bleibtreu, on behalf of the PSL-Covid working group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?